Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.
/ Not yet recruitingNot Applicable A Pilot Pharmacodynamic/Pharmacokinetic Study of SalmeterolXinofoate as a Dry Powder in Combination with Fluticasone in Patients with Asthma for Dose-Scale Bronchodilator Model Development.
/ Not yet recruitingNot Applicable A Pilot Pharmacodynamic/Pharmacokinetic Study of Fluticasone Propionate Administered as a Dry Powder in Patients with Asthma.
100 Clinical Results associated with Oriel Therapeutics, Inc.
0 Patents (Medical) associated with Oriel Therapeutics, Inc.
100 Deals associated with Oriel Therapeutics, Inc.
100 Translational Medicine associated with Oriel Therapeutics, Inc.